| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 浙江亚太药业股份有限公司（简称“亚太药业”）前身为浙江亚太制药厂，创办于1989年，2010年3月16日在深交所正式挂牌上市（股票代码为002370）。公司是集科研、生产、销售于一体的专业化、规模化国家高新技术企业，拥有6个通过国家GMP认证的生产车间，厂房总面积超12万平米。 亚太药业深耕制药产业三十余年，产品聚焦抗感染、抗病毒、消化系统、心血管、解热镇痛等核心赛道，公司以高端化学制剂为核心主业，正加速从传统仿制药向改良型新药及创新药转型。 目前，亚太药业已在中国的各个区域建立了广泛的销售渠道，通过组建营销团队及与专业推广公司合作的方式，建立了覆盖医院、药店和其他商业渠道的营销网络，并积极拓展海外业务。 未来，亚太药业将继续坚守“质量第一、创新引领”的发展理念，深化产业链布局，加大创新药投入，加速创新药研发，丰富创新药管线，致力于成为立足中国、链接全球的创新药研发与产业化平台，为人类健康事业贡献更多力量。 竞争优势 稳定的生产制造能力 亚太药业现拥有的6个GMP生产车间覆盖固体制剂、冻干粉针剂、头孢类及青霉素类等多剂型生产线，具备规模化、多品类协同制造能力。其中普通固体制剂车间年片剂产能12亿片，普通固体制剂车间年胶囊剂产能10亿粒，冻干粉针车间年冻干粉针剂产能5800万针，头孢胶囊车间年头孢类胶囊产能5亿粒，青霉素固体制剂车间年胶囊剂产能4亿粒、片剂产能2.4亿片，头孢粉针车间年头孢类粉针剂产能5000万针。 领先的研发基础设施 亚太药业药物研发中心被认定为“浙江省省级研究院”“浙江省省级高新技术研究开发中心”“浙江省省级企业技术中心”，研发团队被评为“浙江省创新创业团队”。同时以中国药科大学、沈阳药科大学、浙江大学、浙江省医学科学院药物研究所为技术依托，组建了专业、高效的新药开发团队。目前亚太药业累计获授权发明专利17项，实用新型专利14项，构成了稳健的技术护城河。 专业的管理团队 亚太药业核心管理团队拥有十年以上医药行业深耕经验，具备扎实的制药专业技术背景、丰富的企业运营管理能力与敏锐的市场前瞻视野。团队成员深度参与药品研发、生产制造、质量体系建设、受托生产管理等全链条运营工作，主导并顺利通过37次GMP现场检查、国家局注册核查等，拥有成熟的合规管控、体系搭建与风险防控经验。 独有的“制药工业+产业互联网”深度耦合 2026年2月，随着星浩控股正式成为控股股东、邱中勋先生正式担任董事长兼总经理，亚太药业完成了“制药工业+产业互联网”的深度耦合。这一变革带来的不是简单的渠道增量，而是研产销全链条的生态重构。药兜所构建成熟的医药互联网平台将推动亚太药业降低流通成本、提升运营效率、实现全链路可追溯。 | ||||||||||||||||||||||||
| Main Business | 医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 邱中勋 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 宗昊 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（杭州）事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0575-84810101 | ||||||||||||||||||||||||
| Fax No | 0575-84810101 | ||||||||||||||||||||||||
| Website | www.ytyaoye.com | ||||||||||||||||||||||||
| ytdsh@ytyaoye.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 16/03/2010 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.130 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 1.502 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.176B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |